Kinvard Bio

Kinvard Bio is a clinical-stage biotechnology company focused on developing next-generation therapies for autoimmune and inflammatory diseases. The company leverages its proprietary nanobody and small molecule discovery platforms to engineer highly potent and selective drug candidates. Its lead program, KV-001, is a bispecific nanobody targeting both IL-17A and IL-17F, designed to provide superior efficacy in treating conditions like psoriasis and ankylosing spondylitis. Additionally, Kinvard is advancing a pipeline that includes a TYK2 inhibitor and an IL-4RA antagonist. Headquartered in Suzhou, China, the company is led by a team of industry veterans with extensive experience in global drug development. Kinvard aims to deliver innovative, high-quality treatments to patients worldwide suffering from chronic immune-mediated disorders.